



Sosei Announces Start of SD118 Phase I Studies

Tokyo, Japan – 29 May 2007: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that its collaborative project SD118, which is under development for the treatment of neuropathic pain, has commenced Phase I clinical trials.

SD118 is being jointly developed with NeuroDiscovery Ltd (ASX Code: NDL) and its wholly owned subsidiary NeuroSolutions Ltd under a Collaboration Agreement concluded in June 2006. SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy for neuropathic pain.

The study is a double blind, placebo controlled, single dose, sequential group, dose escalation trial in healthy male volunteers to assess the safety, tolerability and pharmacokinetic profile of SD118 administered as an oral capsule. The study, involving some 40 subjects, will be conducted in a single centre in the UK under a CTA regulatory approval.

Mr Shinichi Tamura, President & CEO of Sosei, said: "I am delighted that SD118 has now moved forward into clinical development. This project has the potential to provide a valuable addition to currently available therapies in an area of notable unmet medical need"

Sosei Group Corporation

Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan
Hiroki MAEKAWA, Representative Executive Officer,
E-mail: hmaekawa@sosei.com Tel: **+81-3-5210-3399** Fax: +81-3-5210-3291

Sosei R&D Ltd..

Chesterford Research Park, Saffron Walden, CB10 1XL England
John DAFFURN, SVP Corporate Development,
E-mail: daffurnj@sosei.com Tel: **+44 (0)1799 532 350** Fax: +44 (0)1799 532 351

Financial Dynamics

Julia Phillips

Tel: + 44 (0)207 831 3113

The Trout Group

Thomas Fechtner
Brandon Lewis

Tel: +1 646-378-2915

Tel: +1 646-378-2931

NeuroDiscovery Ltd

David McAuliffe
Level 11 225 St Georges Tce, Perth, WA, Australia
E-mail: macdavid@iinet.net.au

Tel: +61 89 226 4033

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit www.osei.com

About NeuroDiscovery

NeuroDiscovery Ltd is an ASX listed neurology research and development company which owns 100% of NeuroSolutions Ltd (ASX Code: NDL). For further information visit www.neurodiscoveryltd.com.

About NeuroSolutions

NeuroSolutions Limited is a profitable service company, applying its broad expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells, tissues or in vivo. NeuroSolutions current clients include many other established pharmaceutical and biotechnology companies.

In parallel to running its service business, the Company is also exploiting its in house technologies and expertise for its own internal R&D

For further information visit www.nsolns.com.

About Neuropathic Pain

Neuropathic pain is associated with peripheral or central nervous system injury. It is often described as “burning” or “shooting” in nature and can be continuous or paroxysmal. It is estimated that up to 5% of the general population of the USA, Europe and Japan are affected by neuropathic conditions including diabetic neuropathic pain and post-herpetic neuralgia.

The disease is predominantly treated at present with a variety of anticonvulsant, antidepressant and analgesic drugs but many patients fail to respond adequately to these agents. Consequently neuropathic pain is recognised as an area of significant unmet medical need. The global market value for neuropathic pain treatments is currently estimated at \$2.1Bn and is predicted to rise to \$5.5Bn by 2015.